Residual vascular risk in diabetes - Will the SPPARM alpha concept hold the key?

[1]  B. Staels,et al.  The Protein Kinase C Signaling Pathway Regulates a Molecular Switch between Transactivation and Transrepression Activity of the Peroxisome Proliferator-Activated Receptor α , 2004 .

[2]  J. Fruchart,et al.  Selective peroxisome proliferator-activated receptorα modulators (SPPARMα): The next generation of peroxisome proliferator-activated receptor α-agonists , 2013, Cardiovascular Diabetology.

[3]  J. Fruchart.  Peroxisome proliferator-activated receptor-alpha (PPARalpha): at the crossroads of obesity, diabetes and cardiovascular disease. , 2009, Atherosclerosis.

[4]  K. Mahaffey,et al.  Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes , 2017, The New England journal of medicine.

[5]  V. Sládek,et al.  Molecular association model of PPARα and its new specific and efficient ligand, pemafibrate: Structural basis for SPPARMα. , 2018, Biochemical and biophysical research communications.

[6]  M. Davidson.  Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions , 2006, Expert opinion on drug safety.

[7]  J. Borén,et al.  Crosstalk between nonalcoholic fatty liver disease and cardiometabolic syndrome , 2018, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[8]  John B Buse,et al.  Effects of combination lipid therapy in type 2 diabetes mellitus. , 2010, The New England journal of medicine.

[9]  T. Craven,et al.  Reversibility of Fenofibrate Therapy–Induced Renal Function Impairment in ACCORD Type 2 Diabetic Participants , 2012, Diabetes Care.

[10]  S. Nissen,et al.  Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials. , 2007, JAMA.

[11]  Adrian F Hernandez,et al.  Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. , 2017, The lancet. Diabetes & endocrinology.

[12]  A. Keech,et al.  Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease , 2017, The New England journal of medicine.

[13]  Deepak L. Bhatt,et al.  Emerging Mechanisms of Cardiovascular Protection for the Omega-3 Fatty Acid Eicosapentaenoic Acid , 2020, Arteriosclerosis, thrombosis, and vascular biology.

[14]  P. Libby,et al.  Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study , 2018, American heart journal.

[15]  B. Zinman,et al.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2015, The New England journal of medicine.

[16]  I. Issemann,et al.  Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators , 1990, Nature.

[17]  B. Staels,et al.  Drug Insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors , 2007, Nature Clinical Practice Endocrinology &Metabolism.

[18]  N. Marx,et al.  Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. , 2004, Circulation research.

[19]  A. Hoes,et al.  [Guidelines on cardiovascular disease prevention in clinical practice]. , 2005, Revue medicale de Liege.

[20]  B. Staels,et al.  Peroxisome proliterator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis , 1999 .

[21]  Deepak L. Bhatt,et al.  Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome , 2018, The New England journal of medicine.